Research Article

Body Mass Index Is Associated with the Severity and All-Cause Mortality of Acute Kidney Injury in Critically Ill Patients: An Analysis of a Large Critical Care Database

Benji Wang,1 Diwen Li,1 Yuqiang Gong,1 Binyu Ying,1 Bihuan Cheng,1 and Laifang Sun2

1Department of Anesthesiology, Critical Care and Pain Medicine, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou, 325000 Zhejiang, China
2Department of Emergency Intensive Care Unit, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou, 325000 Zhejiang, China

Correspondence should be addressed to Bihuan Cheng; cbh@wmu.edu.cn and Laifang Sun; sunlaifang@wmu.edu.cn

Received 9 December 2020; Revised 1 June 2021; Accepted 21 June 2021; Published 29 June 2021

Academic Editor: Marco Fiore

Copyright © 2021 Benji Wang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Background. Acute kidney injury (AKI) is a common clinical syndrome carrying high morbidity and mortality. Body mass index (BMI) is a common health indicator, and a high BMI value—obesity has been shown to be associated with the outcomes of several diseases. However, the relationship between different BMI categories and mortality in all critically ill patients with AKI is unclear and needs further investigation. Therefore, we evaluated the ability of BMI to predict the severity and all-cause mortality of AKI in critically ill patients.

Methods. We extracted clinical data from the MIMIC-III v1.4 database. All adult patients with AKI were initially screened. The baseline data extracted within 24 hours after ICU admission were presented according to WHO BMI categories. Logistic regression models and the Cox proportional hazards models were, respectively, constructed to assess the relationship between BMI and the severity and all-cause mortality of AKI. The generalized additive model (GAM) was used to identify nonlinear relationships as BMI was a continuous variable. The subgroup analyses were performed to further analyze the stability of the association between BMI category and 365-day all-cause mortality of AKI. Result. A total of 15,174 patients were extracted and were divided into four groups according to BMI. Obese patients were more likely to be young and male. In the fully adjusted logistic regression model, we found that overweight and obesity were significant predictors of AKI stage III (OR, 95 CI: 1.17, 1.05–1.30; 1.32, 1.18–1.47). In the fully adjusted Cox proportional hazards model, overweight and obesity were associated with significantly lower 30-day, 90-day, and 365-day all-cause mortality. The corresponding adjusted HRs (95 CIs) for overweight patients were 0.87 (0.77, 0.99), 0.84 (0.76, 0.93), and 0.80 (0.74, 0.88), and for obese patients, they were 0.87 (0.77, 0.98), 0.79 (0.71, 0.88), and 0.73 (0.66, 0.80), respectively. The subgroup analyses further presented a stable relationship between BMI category and 365-day all-cause mortality. Conclusions. BMI was independently associated with the severity and all-cause mortality of AKI in critical illness. Overweight and obesity were associated with increased risk of AKI stage III; however, they were predictive of a relatively lower mortality risk in these patients.

1. Introduction

Acute kidney injury (AKI) is a common clinical syndrome carrying high morbidity and mortality [1, 2]. Several studies have shown that AKI occurs in a large number of critically ill patients, especially in the intensive care unit (ICU), carrying a very high mortality rate (50–60%) [3, 4]. Worldwide, 21–67% of critically ill patients develop AKI during their ICU stay [5–7], and the morbidity associated with AKI is expected to continue to increase [8]. Patients with AKI sometimes require renal replacement therapy (RRT); however, clinicians often disagree as to when to start RRT [9]. RRT is an invasive and potentially risky treatment that should not be initiated if the patient has mild disease and kidney function could be restored without intervention. However, a conservative approach to initiation of RRT late in the
course of the AKI may lead to adverse outcomes [10]. Therefore, a simple and reliable clinical predictor of AKI severity can better assist clinicians in making decisions.

Body mass index (BMI) is a common health indicator, calculated as the ratio of weight to squared height (kg/m²). The degree of obesity can be classified into categories on the basis of BMI according to the World Health Organization (WHO). Overweight (BMI ≥ 25 to <30 kg/m²) and obesity (BMI ≥ 30 kg/m²) are now common public health problems in both developed and developing countries that give rise to substantial global public burdens [11]. More than half of American adults are overweight or obese, and this proportion is increasing [12, 13]. Studies have shown that obesity is associated with an increased morbidity in cardiovascular disease, diabetes, and depression [14–16], increasing hospital length of stay and medical costs [17, 18].

Previous studies have shown that obese patients have a higher incidence of AKI, more severe renal injury, and higher mortality [19, 20]. Danziger et al. [21] demonstrated that the mortality rate of obese patients with AKI was significantly higher than those without AKI within each BMI category. However, some recent studies have shown that obesity in critically ill patients can improve survival [20, 22]. Soto et al. [23] investigated the association between BMI and AKI in patients with acute respiratory distress syndrome (ARDS) and demonstrated that increased BMI was correlated with increased prevalence of AKI, however, with decreased mortality. In addition, Kim et al. [24] found that in patients with AKI treated with CRRT, a high BMI was beneficial for survival, especially in those with severe illness.

Based on these findings, the relationship between different BMI categories and all-cause mortality in all critically ill patients with AKI is controversial and needs further investigation. Therefore, the aim of this study was to assess the relationship between BMI and the severity and all-cause mortality of AKI in critical illness.

2. Methods

2.1. Data Source. The Multiparameter Intelligent Monitoring in Intensive Care Database III version 1.4 (MIMIC-III v1.4) includes more than 40,000 ICU patients treated at Beth Israel Deaconess Medical Center (Boston, MA, USA) from 2001 to 2012 [25]. We were allowed to access the database after completing the National Institutes of Health’s web-based course and passing the Protecting Human Research Participants exam (No. 6182750). Identifying information was hidden to protect privacy. The project was granted a waiver of informed consent.

2.2. Study Population. All adult patients (≥18 years) with AKI according to Kidney Disease Improving Global Outcomes (KDIGO) definition [26] were initially screened. According to the KDIGO classification, AKI was divided into three stages: I, II, and III. Weight and height values were extracted and calculated to obtain BMI. Depending on the WHO BMI classification, patients were divided into four groups: underweight (BMI < 18.5 kg/m²), normal (BMI: 18.5 to <25 kg/m²), overweight (BMI: 25 to <30 kg/m²), and obese (BMI ≥ 30 kg/m²).

2.3. Data Extraction. As in our previous study [27, 28], we used the PostgreSQL tool (version 9.6) to extract clinical data, including patient demographics, vital signs, laboratory test results, scoring systems, and other clinical variables. Only the data for the first ICU admission of each patient were used, and baseline data were extracted within 24 hours after ICU admission. The vital signs included systolic blood pressure (SBP), diastolic blood pressure (DBP), mean blood pressure (MBP), heart rate, respiratory rate, temperature, and saturation of pulse oxygen (SPO2). These values were the averages of the first 24 hours after admission. The comorbidities included congestive heart failure (CHF), cardiac arrhythmias, valvular disease, hypertension, renal disease, liver disease, uncomplicated diabetes, complicated diabetes, metastatic cancer, and coagulopathy. Laboratory measurements included anion gap, bicarbonate, creatinine, chloride, glucose, hematocrit, hemoglobin, platelet, sodium, potassium, lactate, blood urea nitrogen (BUN), white blood cells (WBC), prothrombin time (PT), activated partial thromboplastin time (APTT), and international normalized ratio (INR). Sequential organ failure assessment (SOFA) scores [29] and simplified acute physiology scores II (SAPSII) [30] were calculated for each patient at the time of ICU admission. The endpoints were AKI stage III during ICU stay and 30-day, 90-day, and 365-day all-cause mortality.

2.4. Statistical Analysis. Baseline characteristics of all patients were stratified in four groups on the basis of the WHO BMI classification. Continuous variables were expressed as mean ± standard deviation (SD) and were compared using one-way ANOVA across groups. Categorical data were expressed as number or percentage and were compared using the chi-squared test or Fisher’s exact test.

Logistic regression models were constructed to determine whether BMI was independently associated with the severity of AKI, and the Cox proportional hazards models were used to evaluate the relationship between BMI and all-cause mortality. The normal-weight group was the reference, and the results were presented as odds ratios (ORs) or hazard ratios (HRs) with 95% confidence intervals (95 CIs). Variables based on epidemiological and biological background were incorporated as potential confounders, and these confounders were adjusted based on a change in effect estimate of >10% when added to the model [31]. Because BMI was a continuous variable, a generalized additive model (GAM) was used to identify nonlinear relationships. We performed subgroup analyses to further analyze the association between BMI category and 365-day all-cause mortality of AKI. Modifications and interactions of subgroups were evaluated using likelihood ratio tests.

The data were analyzed using the R software version 3.42 (http://www.R-project.org, The R Foundation) and EmpowerStats version 2.17.8 (http://www.empowerstats.com, X&Y Solutions, Inc., Boston, MA). P < 0.05 was considered statistically significant, and all reported P values were two-sided.
3. Results

3.1. Subject Characteristics. Characteristics of the participants are displayed in Table 1. A total of 15,174 patients who met the inclusion criteria were divided into groups according to BMI. There were four groups: 378 patients were in the underweight group, 4,683 patients were in the normal group, 5,084 patients were in the overweight group, and 5,029 patients were in the obese group. Obese patients were more likely to be young and male; with faster respiratory rate and lower SPO2; and with higher anion gap, bicarbonate, creatinine, glucose, BUN, WBC, hematocrit, and hemoglobin levels, as well as higher comorbidities of diabetes compared with normal patients. Furthermore, obese patients had worse SOFA scores, longer length of stay in the ICU, and lower mortality than the normal-BMI patients.

3.2. BMI Values and Severity of AKI. In multivariate logistic regression models (Table 2), adjusted for age, gender, and ethnicity, overweight and obesity were significant predictors of AKI stage III during ICU stay. The corresponding adjusted ORs (95 CIs) for overweight and obese groups compared to the normal group were 1.14 (1.05, 1.24) and 1.28 (1.18, 1.39), respectively. In model II, after adjusting for age, gender, ethnicity, CHF, cardiac arrhythmias, valvular disease, hypertension, uncomplicated diabetes, complicated diabetes, renal failure, liver disease, metastatic cancer, coagulopathy, alcohol abuse, drug abuse, anion gap, bicarbonate, glucose, creatinine, chloride, hemoglobin, lactate, platelet, potassium, APTT, PT, sodium, BUN, WBC, heart rate, SBP, respiratory rate, temperature, SPO2, ICU length of stay, SOFA score, and SAPSII score, we found that overweight and obesity remained significant predictors of AKI stage III (OR, 95 CI: 1.17, 1.05–1.30; 1.32, 1.18–1.47, respectively). The underweight group was not independently associated with this clinical endpoint. As a continuous variable, the relationship between admission BMI values and AKI stage III was nearly positively linear (Figure 1).

3.3. BMI Values and All-Cause Mortality of AKI. Covariates were also adjusted in the Cox proportional hazards models (Table 3). In the fully adjusted model (model II), covariates were adjusted for age, gender, ethnicity, CHF, cardiac arrhythmias, valvular disease, hypertension, uncomplicated diabetes, complicated diabetes, renal failure, liver disease, metastatic cancer, coagulopathy, alcohol abuse, anion gap, bicarbonate, glucose, creatinine, chloride, lactate, potassium, APTT, INR, BUN, WBC, heart rate, SBP, DBP, respiratory rate, temperature, SPO2, ICU length of stay, AKI stage, SOFA score, and SAPSII score. Overweight and obesity were associated with significantly lower 30-day, 90-day, and 365-day all-cause mortality than those of the normal group. The corresponding adjusted HRs (95 CIs) for overweight patients were 0.87 (0.77, 0.99), 0.84 (0.76, 0.93), and 0.80 (0.74, 0.88), and those for obese patients were 0.87 (0.77, 0.98), 0.79 (0.71, 0.88), and 0.73 (0.66, 0.80), respectively. Similarly, underweight was not independently associated with all-cause mortality, and BMI was negatively correlated with 365-day all-cause mortality (Figure 2).

3.4. Subgroup Analyses. We conducted subgroup analyses to investigate the stability of the associations between BMI category and 365-day all-cause mortality (Table 4). There were no interactions in most strata (P = 0.0546-0.9671). We only observed significant interactions in potassium, lactate, MBP, platelet, SBP, sodium, bicarbonate, and temperature (P for interaction: 0.0005, 0.0008, 0.0019, 0.0041, 0.0074, 0.0100, 0.0121, and 0.0173, respectively). However, BMI was a protective factor in all of these interactive stratifications, and as BMI increased, all-cause mortality in the context of AKI decreased.

4. Discussion

We included a total of 15,174 patients. In multivariate analysis, after adjusting for age, ethnicity, gender, and other confounding factors, overweight and obesity were associated with increased risk of AKI stage III in critically ill patients, as has previously been reported. However, overweight and obesity were predictive of a relatively lower mortality risk in these patients.

These findings suggest that clinicians should be aware of the possibility of severe AKI in obese patients. Interestingly, obesity is not necessarily an adverse risk factor in critically ill patients with AKI, which is consistent with previously reported survival benefits for critically ill patients with obesity. Previous studies have shown a high morbidity of AKI in critically ill patients during ICU stay [2, 32], while the specific pathogenesis of AKI has remained unclear to date. Obese patients have distinct risk factors for more comorbidities, including hypertension, dyslipidemia, coronary heart disease, and respiratory and cardiovascular failure to present [33–35]. Weight loss after gastric bypass surgery reduced long-term total mortality significantly and particularly improved the prognosis of cancer, heart disease, and diabetes [36, 37]. A retrospective study showed that obesity was associated with increased development of AKI, and increased BMI was associated with decreased mortality in ARDS patients [23]. Another study demonstrated that obesity was associated with short- and long-term survival advantages in patients with sepsis [38]. Our findings in the overweight and obese cohort were in accordance with these two studies.

Studies on the pathophysiological mechanisms between obesity and AKI are limited, but some progress has been made, and the following possible mechanisms are currently believed to exist. Obesity may result in renal compression, leading to increased intrarenal pressure, decreased blood flow to the loop of Henle, and ultimately renal injury [39, 40]. The renin angiotensin aldosterone system (RAAS) in obese people is generally moderately activated, with increased levels of angiotensin II (AngII) and aldosterone [34]. Low levels of AngII increase the reabsorption of sodium by the peritubular capillary, exacerbating the adverse effects of increased blood pressure. AngII increases the hydrostatic pressure of the glomerulus, causing decreased renal perfusion [41]. It has been suggested that there might be an association between leptin and renal injury. Leptin levels tended to be high in obese people, but
| Characteristic                     | Underweight (<18.5) | Normal (≥18.5, <25) | Overweight (≥25, <30) | Obese (≥30) | P value |
|-----------------------------------|----------------------|---------------------|-----------------------|-------------|---------|
| **Clinical parameters (n)**       | 378                  | 4683                | 5084                  | 5029        |         |
| **BMI (kg/m²)**                   | 17.63 ± 0.58         | 22.46 ± 1.73        | 27.38 ± 1.41          | 35.91 ± 5.60 | <0.001  |
| **Age (years)**                   | 87.05 ± 71.09        | 81.42 ± 61.16       | 74.72 ± 47.22         | 66.80 ± 31.95 | <0.001  |
| **Gender, n (%)**                 |                      |                     |                       |             | <0.001  |
| Female                            | 225 (59.52)          | 2000 (42.71)        | 1672 (32.89)          | 2056 (40.88) |         |
| Male                              | 153 (40.48)          | 2683 (57.29)        | 3412 (67.11)          | 2973 (59.12) |         |
| **Ethnicity, n (%)**              |                      |                     |                       |             | 0.023   |
| White                             | 260 (68.78)          | 3296 (70.38)        | 3658 (71.95)          | 3622 (72.02) |         |
| Black                             | 46 (12.17)           | 414 (8.84)          | 405 (7.97)            | 452 (8.99)  |         |
| Other                             | 72 (19.05)           | 973 (20.78)         | 1021 (20.08)          | 955 (18.99) |         |
| **SBP (mmHg)**                    | 116 ± 17             | 116 ± 17            | 116 ± 16              | 116 ± 16    | 0.501   |
| **DBP (mmHg)**                    | 59 ± 11              | 59 ± 11             | 59 ± 10               | 59 ± 19     | 0.001   |
| **MBP (mmHg)**                    | 76 ± 11              | 77 ± 11             | 77 ± 11               | 76 ± 10     | 0.245   |
| **Heart rate (beats/minute)**     | 87 ± 16              | 86 ± 15             | 86 ± 15               | 87 ± 16     | 0.006   |
| **Respiratory rate (beats/minute)** | 19 ± 4              | 19 ± 4              | 18 ± 4               | 19 ± 4     | <0.001  |
| **Temperature (°C)**              | 36.7 ± 0.6           | 36.8 ± 0.7          | 36.8 ± 0.7            | 36.9 ± 0.7  | <0.001  |
| **SPO₂**                          | 98 ± 2.7             | 98 ± 2.3            | 97 ± 2.2              | 97 ± 2.3    | <0.001  |
| **Comorbidities, n (%)**          |                      |                     |                       |             |         |
| Congestive heart failure          | 71 (18.78)           | 816 (17.42)         | 766 (15.07)           | 868 (17.26) | 0.003   |
| Cardiac arrhythmias               | 65 (17.20)           | 891 (19.03)         | 824 (16.21)           | 917 (18.23) | 0.002   |
| Valvular disease                  | 28 (7.41)            | 332 (7.09)          | 241 (4.74)            | 263 (5.23)  | <0.001  |
| Hypertension                      | 55 (14.55)           | 749 (15.99)         | 815 (16.03)           | 824 (16.38) | 0.794   |
| Renal disease                     | 75 (19.84)           | 907 (19.37)         | 977 (19.22)           | 973 (19.35) | 0.994   |
| Liver disease                     | 29 (7.67)            | 352 (7.52)          | 349 (6.86)            | 410 (8.15)  | 0.109   |
| Uncomplicated diabetes            | 38 (10.05)           | 784 (16.74)         | 1084 (21.32)          | 1556 (30.94) | <0.001  |
| Complicated diabetes              | 27 (7.14)            | 303 (6.47)          | 397 (7.81)            | 569 (11.31) | <0.001  |
| Metastatic cancer                 | 20 (5.29)            | 189 (4.04)          | 179 (3.52)            | 127 (2.53)  | <0.001  |
| Coagulopathy                      | 68 (17.99)           | 711 (15.18)         | 740 (14.56)           | 712 (14.16) | 0.145   |
| **Laboratory parameters**         |                      |                     |                       |             |         |
| Anion gap (mmol/L)                | 12.94 ± 3.52         | 12.95 ± 3.47        | 12.90 ± 3.39          | 13.13 ± 3.29 | <0.001  |
| Bicarbonate (mmol/L)              | 21.48 ± 5.64         | 21.61 ± 4.91        | 21.67 ± 4.48          | 22.20 ± 4.91 | <0.001  |
| Creatinine (mEq/L)                | 1.38 ± 1.38          | 1.50 ± 1.66         | 1.49 ± 1.57           | 1.56 ± 1.54 | <0.001  |
| Chloride (mmol/L)                 | 101.98 ± 7.75        | 102.15 ± 6.51       | 102.61 ± 6.17         | 102.03 ± 6.04 | 0.079   |
| Glucose (mg/dL)                   | 132.99 ± 40.54       | 136.06 ± 40.48      | 141.39 ± 42.31        | 148.23 ± 45.24 | <0.001  |
| Hematocrit                        | 27.93 ± 6.11         | 27.69 ± 6.17        | 28.09 ± 6.18          | 28.68 ± 6.25 | <0.001  |
| Hemoglobin (g/dL)                 | 9.35 ± 2.01          | 9.37 ± 2.12         | 9.52 ± 2.14           | 9.67 ± 2.14 | <0.001  |
| Platelet (10⁹/L)                  | 211.58 ± 127.66      | 188.25 ± 112.69     | 181.20 ± 101.84       | 188.18 ± 101.33 | <0.001  |
| Sodium (mmol/L)                   | 136.16 ± 6.05        | 135.72 ± 5.07       | 135.77 ± 4.56         | 135.96 ± 4.84 | 0.005   |
| Potassium (mmol/L)                | 3.72 ± 0.60          | 3.71 ± 0.56         | 3.73 ± 0.55           | 3.79 ± 0.57  | <0.001  |
| Lactate (mmol/L)                  | 1.74 ± 0.95          | 1.76 ± 1.29         | 1.73 ± 1.27           | 1.76 ± 1.19  | 0.130   |
| BUN (mg/dL)                       | 26.59 ± 21.97        | 26.39 ± 21.27       | 26.03 ± 20.38         | 28.21 ± 21.77 | <0.001  |
| WBC (10⁹/L)                       | 10.29 ± 6.38         | 10.40 ± 6.73        | 10.77 ± 11.30         | 11.00 ± 6.50 | <0.001  |
| PT (seconds)                      | 14.89 ± 3.98         | 14.94 ± 4.54        | 14.97 ± 4.79          | 15.14 ± 4.82 | 0.002   |
| APTT (seconds)                    | 33.71 ± 13.12        | 33.56 ± 12.80       | 32.90 ± 12.48         | 31.67 ± 10.99 | <0.001  |
| INR                               | 1.37 ± 0.54          | 1.38 ± 0.63         | 1.38 ± 0.61           | 1.40 ± 0.65  | 0.009   |

**Table 1:** Baseline characteristics of participants according to BMI category (N = 15174).
dropped rapidly after fasting [42]. Patients with chronic kidney disease (CKD) had elevated leptin due to reduced plasma clearance [43]. Studies have shown that these high levels of leptin might in turn lead to faster declines in renal clearance both through the direct effects of nephron disruption and indirect effects through inflammatory responses [44].

Recently, the findings on obesity and prognosis of disease have been challenged, and the obesity paradox has been hotly debated. This paradox is characterized by observations that some adverse outcomes occur less frequently in overweight or obese people than in those with normal weight. Nevertheless, it is unclear whether this phenomenon is definitive, as the underlying mechanisms remain poorly understood. In our final regression model, after adjusting for relevant confounders, the survival benefits of overweight and obese patients remained substantial.

Table 1: Continued.

| Characteristic         | Underweight (<18.5) | Normal (≥18.5, <25) | Overweight (≥25, <30) | Obese (≥30) | P value |
|------------------------|---------------------|---------------------|-----------------------|-------------|---------|
| Scoring systems        |                      |                     |                       |             |         |
| SOFA                   | 4.92 ± 2.96         | 5.17 ± 3.19         | 5.31 ± 3.23           | 5.57 ± 3.34 | <0.001  |
| SAPSII                 | 40.85 ± 13.49       | 39.71 ± 13.94       | 38.87 ± 13.80         | 38.71 ± 14.22 | <0.001  |
| Alcohol abuse          | 15 (3.97)           | 277 (5.92)          | 307 (6.04)            | 317 (6.30)  | 0.307   |
| Drug abuse             | 11 (2.91)           | 166 (3.54)          | 136 (2.68)            | 119 (2.37)  | 0.005   |
| ICU LOS (day)          | 5.79 ± 6.59         | 5.96 ± 7.70         | 6.07 ± 8.14           | 6.65 ± 8.31 | <0.001  |

Table 2: Relationship between BMI and AKI stage III in different models.

| Variable               | Crude model | Model I | Model II |
|------------------------|-------------|---------|----------|
|                       | OR (95 CIs) | P value | OR (95 CIs) | P value | OR (95 CIs) | P value |
| BMI (kg/m²)            |             |         |           |         |           |         |
| <18.5                  | 1.02 (1.01, 1.02) | <0.0001 | 1.02 (1.02, 1.03) | <0.0001 | 1.02 (1.02, 1.03) | <0.0001 |
| ≥18.5, <25             | 0.74 (0.60, 0.91) | 0.0042  | 0.74 (0.60, 0.91) | 0.0048  | 0.78 (0.59, 1.03) | 0.0828  |
| ≥25, <30               | 1.14 (1.05, 1.24) | 0.0017  | 1.14 (1.05, 1.24) | 0.0013  | 1.17 (1.05, 1.30) | 0.0055  |
| ≥30                    | 1.26 (1.16, 1.37) | <0.0001 | 1.28 (1.18, 1.39) | <0.0001 | 1.32 (1.18, 1.47) | <0.0001 |

OR: odds ratio; CI: confidence interval. Models were derived from logistic multivariate regression models. The crude model was adjusted for none. The Adjust I model was adjusted for age, gender, and ethnicity. The Adjust II model was adjusted for age, gender, ethnicity, congestive heart failure, cardiac arrhythmias, valvular disease, hypertension, uncomplicated diabetes, complicated diabetes, renal failure, liver disease, metastatic cancer, coagulopathy, alcohol abuse, drug abuse, anion gap, bicarbonate, glucose, creatinine, chloride, hemoglobin, lactate, platelet, potassium, APTT, PT, sodium, BUN, WBC, heart rate, systolic blood pressure, respiratory rate, temperature, SPO₂, ICU length of stay, SAPSII, and SOFA.

Figure 1: The relationship between BMI values and AKI stage III.

Figure 1: The relationship between BMI values and AKI stage III.
Niedziela et al. demonstrated that, in episodes of high catabolic responses in critical illness, the nutritional reserve level of obese people and the corresponding increase of energy supply may be crucial for improving the outcome of AKI [45]. Furthermore, adipocytes release adipokine and inflammatory cytokines, including interleukin-10 and interleukin-18, possibly alleviating harmful immune responses, thereby helping to improve survival in critical illness [46]. Obese patients are more likely to receive attention from medical staff, and because of their predisposition to complications and defective physiological reserves, they tend to be treated earlier and more aggressively [47].

Our study has several limitations. First, as a retrospective single-center analysis, bias was inevitable; this may have affected the results to some extent. Second, we did not evaluate indicators of obesity other than BMI, and whether a high BMI value is necessarily indicative of obesity. These uncertainties may have effects on our conclusions. Third, the weight data used to calculate BMI were actual weight of the first day, which might lead to biases as critically ill related fluid retention could not be ignored. Fourth, because of the lack of renal function data before ICU admission, we were unable to assess the CKD status among patients with AKI. Fifth, we did not consider the timing of AKI. Finally, our study only tested associations, not internal mechanisms; therefore, further studies, are needed to confirm this relationship.

Table 3: HRs (95 CIs) for mortality across groups of BMI.

| Variable                  | Crude model |          |          |          |
|---------------------------|-------------|----------|----------|----------|
|                           | HR (95 CIs) | P value  | HR (95 CIs) | P value  | HR (95 CIs) | P value  |
| 30-day all-cause mortality|             |          |          |          |
| BMI (kg/m²)               | 0.98 (0.98, 0.99) | <0.0001 | 0.99 (0.98, 0.99) | 0.0002 | 0.99 (0.98, 1.00) | 0.0092 |
| BMI (category) (kg/m²)    |             |          |          |          |
| <18.5                    | 1.16 (0.95, 1.42) | 0.1438 | 1.14 (0.93, 1.39) | 0.2147 | 0.96 (0.75, 1.22) | 0.7228 |
| ≥18.5, <25               | 1.0(ref)    |          | 1.0(ref) |          |
| ≥25, <30                 | 0.77 (0.69, 0.85) | <0.0001 | 0.80 (0.72, 0.89) | <0.0001 | 0.87 (0.77, 0.99) | 0.0287 |
| ≥30                      | 0.74 (0.67, 0.82) | <0.0001 | 0.80 (0.72, 0.88) | <0.0001 | 0.87 (0.77, 0.98) | 0.0250 |
| 90-day all-cause mortality|             |          |          |          |
| BMI (kg/m²)               | 0.98 (0.97, 0.98) | <0.0001 | 0.98 (0.98, 0.99) | <0.0001 | 0.98 (0.98, 0.99) | <0.0001 |
| BMI (category) (kg/m²)    |             |          |          |          |
| <18.5                    | 1.31 (1.11, 1.54) | 0.0012 | 1.29 (1.10, 1.52) | 0.0021 | 1.05 (0.86, 1.28) | 0.6311 |
| ≥18.5, <25               | 1.0(ref)    |          | 1.0(ref) |          |
| ≥25, <30                 | 0.76 (0.70, 0.83) | <0.0001 | 0.79 (0.72, 0.86) | <0.0001 | 0.84 (0.76, 0.93) | 0.0012 |
| ≥30                      | 0.72 (0.66, 0.78) | <0.0001 | 0.77 (0.71, 0.84) | <0.0001 | 0.79 (0.71, 0.88) | <0.0001 |
| 365-day all-cause mortality|             |          |          |          |
| BMI (kg/m²)               | 0.97 (0.97, 0.98) | <0.0001 | 0.98 (0.97, 0.98) | <0.0001 | 0.98 (0.97, 0.98) | <0.0001 |
| BMI (category) (kg/m²)    |             |          |          |          |
| <18.5                    | 1.40 (1.23, 1.60) | <0.0001 | 1.38 (1.21, 1.58) | <0.0001 | 1.16 (0.98, 1.36) | 0.0878 |
| ≥18.5, <25               | 1.0(ref)    |          | 1.0(ref) |          |
| ≥25, <30                 | 0.73 (0.68, 0.79) | <0.0001 | 0.76 (0.71, 0.82) | <0.0001 | 0.80 (0.74, 0.88) | <0.0001 |
| ≥30                      | 0.68 (0.63, 0.73) | <0.0001 | 0.73 (0.68, 0.79) | <0.0001 | 0.73 (0.66, 0.80) | <0.0001 |

HR: hazard ratio; CI: confidence interval. Models were derived from the Cox proportional hazards regression models. The crude model was adjusted for none. The Adjust I model was adjusted for age, gender, and ethnicity. The Adjust II model was adjusted for age, gender, ethnicity, congestive heart failure, cardiac arrhythmias, valvular disease, hypertension, uncomplicated diabetes, complicated diabetes, renal failure, liver disease, metastatic cancer, coagulopathy, alcohol abuse, anion gap, bicarbonate, glucose, creatinine, chloride, lactate, potassium, activated partial thromboplastin time, international normalized ratio, blood urea nitrogen, white blood cell, heart rate, systolic blood pressure, diastolic blood pressure, respiratory rate, temperature, SPO₂, ICU length of stay, AKI stage, SAPSII, and SOFA.

Figure 2: The relationship between BMI values and 365-day mortality of AKI.
Table 4: Subgroup analysis of the associations between BMI category and 365-day all-cause mortality.

|                                | No. of patients | <18.5 | ≥18.5, <25 | ≥25, <30 | ≥30 | P for interaction |
|--------------------------------|-----------------|-------|------------|----------|-----|------------------|
| CHF                            |                 |       |            |          |     | 0.9671           |
| No                             | 12653           | 1.44  | (1.21, 1.73)| 1.0 (ref)| 0.74 (0.68, 0.81)| 0.73 (0.67, 0.79)|
| Yes                            | 2521            | 1.15  | (0.85, 1.57)| 1.0 (ref)| 0.87 (0.75, 0.99)| 0.69 (0.60, 0.80)|
| Cardiac arrhythmias            |                 |       |            |          |     | 0.1640           |
| No                             | 12477           | 1.47  | (1.23, 1.76)| 1.0 (ref)| 0.74 (0.68, 0.81)| 0.72 (0.66, 0.79)|
| Yes                            | 2697            | 1.18  | (0.85, 1.62)| 1.0 (ref)| 0.85 (0.75, 0.97)| 0.71 (0.62, 0.81)|
| Valvular disease               |                 |       |            |          |     | 0.2122           |
| No                             | 14310           | 1.48  | (1.26, 1.73)| 1.0 (ref)| 0.77 (0.71, 0.83)| 0.74 (0.68, 0.80)|
| Yes                            | 864             | 0.61  | (0.33, 1.13)| 1.0 (ref)| 0.87 (0.68, 1.10)| 0.71 (0.55, 0.91)|
| Hypertension                   |                 |       |            |          |     | 0.3760           |
| No                             | 12731           | 1.39  | (1.17, 1.65)| 1.0 (ref)| 0.74 (0.68, 0.81)| 0.73 (0.67, 0.80)|
| Yes                            | 2443            | 1.36  | (0.95, 1.95)| 1.0 (ref)| 0.83 (0.71, 0.96)| 0.70 (0.59, 0.82)|
| Uncomplicated diabetes         |                 |       |            |          |     | 0.4680           |
| No                             | 11712           | 1.37  | (1.16, 1.62)| 1.0 (ref)| 0.78 (0.72, 0.85)| 0.77 (0.71, 0.84)|
| Yes                            | 3462            | 1.45  | (0.94, 2.23)| 1.0 (ref)| 0.68 (0.58, 0.80)| 0.61 (0.52, 0.71)|
| Complicated diabetes           |                 |       |            |          |     | 0.5448           |
| No                             | 13878           | 1.34  | (1.14, 1.58)| 1.0 (ref)| 0.75 (0.70, 0.81)| 0.73 (0.67, 0.78)|
| Yes                            | 1296            | 1.93  | (1.13, 3.27)| 1.0 (ref)| 0.86 (0.67, 1.10)| 0.74 (0.58, 0.94)|
| Metastatic cancer              |                 |       |            |          |     | 0.1714           |
| No                             | 14659           | 1.40  | (1.19, 1.64)| 1.0 (ref)| 0.76 (0.70, 0.82)| 0.74 (0.69, 0.80)|
| Yes                            | 515             | 0.87  | (0.51, 1.48)| 1.0 (ref)| 0.82 (0.64, 1.04)| 0.82 (0.62, 1.07)|
| Coagulopathy                   |                 |       |            |          |     | 0.1361           |
| No                             | 12943           | 1.38  | (1.16, 1.65)| 1.0 (ref)| 0.74 (0.68, 0.81)| 0.69 (0.63, 0.75)|
| Yes                            | 2231            | 1.32  | (0.95, 1.83)| 1.0 (ref)| 0.88 (0.75, 1.03)| 0.97 (0.83, 1.13)|
| Renal disease                  |                 |       |            |          |     | 0.1568           |
| No                             | 12242           | 1.39  | (1.16, 1.67)| 1.0 (ref)| 0.74 (0.68, 0.81)| 0.74 (0.68, 0.81)|
| Yes                            | 2932            | 1.26  | (0.92, 1.72)| 1.0 (ref)| 0.82 (0.72, 0.94)| 0.68 (0.59, 0.78)|
| Liver disease                  |                 |       |            |          |     | 0.0794           |
| No                             | 14034           | 1.40  | (1.19, 1.65)| 1.0 (ref)| 0.76 (0.70, 0.82)| 0.71 (0.66, 0.77)|
| Yes                            | 1140            | 1.07  | (0.61, 1.90)| 1.0 (ref)| 0.89 (0.70, 1.12)| 0.92 (0.74, 1.16)|
| Alcohol abuse                  |                 |       |            |          |     | 0.1953           |
| No                             | 14258           | 1.36  | (1.16, 1.59)| 1.0 (ref)| 0.75 (0.70, 0.81)| 0.71 (0.66, 0.77)|
| Yes                            | 916             | 1.70  | (0.74, 3.95)| 1.0 (ref)| 0.99 (0.71, 1.38)| 1.18 (0.86, 1.63)|
| Drug abuse                     |                 |       |            |          |     | 0.2702           |
| No                             | 14742           | 1.39  | (1.19, 1.63)| 1.0 (ref)| 0.77 (0.71, 0.82)| 0.73 (0.67, 0.78)|
| Yes                            | 432             | 0.60  | (0.14, 2.51)| 1.0 (ref)| 0.56 (0.33, 0.94)| 0.80 (0.49, 1.31)|
| Heart rate (beats/minute)      |                 |       |            |          |     | 0.0775           |
| <85                            | 7600            | 1.21  | (0.95, 1.53)| 1.0 (ref)| 0.71 (0.64, 0.79)| 0.73 (0.65, 0.81)|
| ≥85                            | 7548            | 1.52  | (1.24, 1.87)| 1.0 (ref)| 0.82 (0.74, 0.91)| 0.74 (0.67, 0.82)|
| SBP (mmHg)                     |                 |       |            |          |     | 0.0074           |
| <114                           | 7585            | 1.22  | (0.98, 1.51)| 1.0 (ref)| 0.81 (0.74, 0.90)| 0.78 (0.71, 0.86)|
| ≥114                           | 7551            | 1.56  | (1.25, 1.95)| 1.0 (ref)| 0.70 (0.62, 0.78)| 0.67 (0.60, 0.75)|
| DBP (mmHg)                     |                 |       |            |          |     | 0.2996           |
| <58                            | 7595            | 1.27  | (1.02, 1.58)| 1.0 (ref)| 0.82 (0.74, 0.90)| 0.79 (0.71, 0.87)|
| ≥58                            | 7540            | 1.48  | (1.19, 1.84)| 1.0 (ref)| 0.70 (0.62, 0.78)| 0.67 (0.60, 0.74)|
| MBP (mmHg)                     |                 |       |            |          |     | 0.0019           |
| <75                            | 7591            | 1.27  | (1.02, 1.58)| 1.0 (ref)| 0.82 (0.74, 0.90)| 0.78 (0.71, 0.87)|
| ≥75                            | 7557            | 1.49  | (1.19, 1.85)| 1.0 (ref)| 0.70 (0.63, 0.78)| 0.67 (0.60, 0.75)|
Table 4: Continued.

| Parameter                        | No. of patients | <18.5 | ≥18.5, <25 | ≥25, <30 | ≥30 | P for interaction |
|----------------------------------|----------------|-------|------------|----------|-----|------------------|
| Respiratory rate (beats/minute)  |                |       |            |          |     | 0.0546           |
| <18                              | 7607           | 1.41  | (1.10, 1.80)| 1.0 (ref)| 0.71 (0.63, 0.79)| 0.73 (0.65, 0.82)|
| ≥19                              | 7531           | 1.32  | (1.08, 1.61)| 1.0 (ref)| 0.80 (0.73, 0.88)| 0.69 (0.63, 0.76)|
| Temperature (°C)                 |                |       |            |          |     | 0.0173           |
| <36.8                            | 7315           | 1.27  | (1.04, 1.54)| 1.0 (ref)| 0.76 (0.69, 0.84)| 0.77 (0.70, 0.85)|
| ≥36.8                            | 7326           | 1.56  | (1.20, 2.02)| 1.0 (ref)| 0.78 (0.70, 0.88)| 0.71 (0.63, 0.80)|
| SPO2                             |                |       |            |          |     | 0.1292           |
| <98                              | 7574           | 1.24  | (0.98, 1.56)| 1.0 (ref)| 0.71 (0.64, 0.78)| 0.63 (0.57, 0.69)|
| ≥98                              | 7599           | 1.54  | (1.25, 1.90)| 1.0 (ref)| 0.80 (0.72, 0.89)| 0.80 (0.71, 0.90)|
| Anion gap (mmol/L)               |                |       |            |          |     | 0.2197           |
| <13                              | 7128           | 1.62  | (1.28, 2.04)| 1.0 (ref)| 0.68 (0.61, 0.77)| 0.69 (0.61, 0.79)|
| ≥13                              | 7551           | 1.27  | (1.02, 1.57)| 1.0 (ref)| 0.81 (0.74, 0.89)| 0.72 (0.66, 0.79)|
| Bicarbonate (mg/dL)              |                |       |            |          |     | 0.0121           |
| <22                              | 6609           | 1.20  | (0.97, 1.49)| 1.0 (ref)| 0.82 (0.74, 0.90)| 0.82 (0.74, 0.91)|
| ≥22                              | 8470           | 1.58  | (1.26, 1.98)| 1.0 (ref)| 0.71 (0.64, 0.79)| 0.67 (0.60, 0.74)|
| Creatinine (mEq/L)               |                |       |            |          |     | 0.4265           |
| <1.0                             | 6950           | 1.68  | (1.32, 2.14)| 1.0 (ref)| 0.72 (0.64, 0.82)| 0.65 (0.56, 0.74)|
| ≥1.0                             | 8188           | 1.21  | (0.99, 1.48)| 1.0 (ref)| 0.74 (0.68, 0.81)| 0.67 (0.61, 0.73)|
| BUN (mg/dL)                      |                |       |            |          |     | 0.6121           |
| <20                              | 7467           | 1.83  | (1.41, 2.36)| 1.0 (ref)| 0.71 (0.62, 0.81)| 0.64 (0.56, 0.74)|
| ≥20                              | 7669           | 1.13  | (0.93, 1.38)| 1.0 (ref)| 0.78 (0.71, 0.85)| 0.70 (0.64, 0.76)|
| WBC (10^9/L)                     |                |       |            |          |     | 0.8296           |
| <9.6                             | 7477           | 1.35  | (1.09, 1.68)| 1.0 (ref)| 0.74 (0.67, 0.82)| 0.74 (0.66, 0.82)|
| ≥9.6                             | 7587           | 1.43  | (1.14, 1.79)| 1.0 (ref)| 0.77 (0.70, 0.86)| 0.71 (0.65, 0.79)|
| Hematocrit                       |                |       |            |          |     | 0.1928           |
| <27.8                            | 7577           | 1.57  | (1.26, 1.94)| 1.0 (ref)| 0.79 (0.71, 0.87)| 0.70 (0.71, 0.88)|
| ≥27.8                            | 7562           | 1.19  | (0.95, 1.49)| 1.0 (ref)| 0.74 (0.66, 0.81)| 0.67 (0.61, 0.74)|
| Hemoglobin (g/dL)                |                |       |            |          |     | 0.1746           |
| <9.4                             | 7558           | 1.51  | (1.23, 1.86)| 1.0 (ref)| 0.78 (0.70, 0.86)| 0.77 (0.69, 0.85)|
| ≥9.4                             | 7565           | 1.21  | (0.95, 1.52)| 1.0 (ref)| 0.75 (0.67, 0.83)| 0.69 (0.62, 0.77)|
| Platelet (10^9/L)                |                |       |            |          |     | 0.0041           |
| <169                             | 7599           | 1.35  | (1.06, 1.71)| 1.0 (ref)| 0.73 (0.66, 0.81)| 0.80 (0.72, 0.88)|
| ≥169                             | 7497           | 1.41  | (1.14, 1.73)| 1.0 (ref)| 0.80 (0.72, 0.89)| 0.67 (0.60, 0.75)|
| Potassium (mmol/L)               |                |       |            |          |     | 0.0005           |
| <3.7                             | 6825           | 1.45  | (1.15, 1.84)| 1.0 (ref)| 0.79 (0.70, 0.88)| 0.85 (0.76, 0.95)|
| ≥3.7                             | 8322           | 1.32  | (1.07, 1.63)| 1.0 (ref)| 0.74 (0.67, 0.81)| 0.64 (0.58, 0.70)|
| Sodium (mmol/L)                  |                |       |            |          |     | 0.0100           |
| <136                             | 6723           | 1.32  | (1.04, 1.67)| 1.0 (ref)| 0.82 (0.74, 0.91)| 0.78 (0.70, 0.88)|
| ≥136                             | 8422           | 1.40  | (1.14, 1.72)| 1.0 (ref)| 0.72 (0.65, 0.79)| 0.69 (0.62, 0.76)|
| Chloride (mmol/L)                |                |       |            |          |     | 0.2410           |
| <103                             | 7245           | 1.29  | (1.05, 1.59)| 1.0 (ref)| 0.80 (0.73, 0.88)| 0.70 (0.64, 0.78)|
| ≥103                             | 7857           | 1.43  | (1.13, 1.81)| 1.0 (ref)| 0.75 (0.67, 0.83)| 0.76 (0.68, 0.85)|
| PT (seconds)                     |                |       |            |          |     | 0.3228           |
| <13.9                            | 6958           | 1.41  | (1.11, 1.80)| 1.0 (ref)| 0.71 (0.64, 0.80)| 0.62 (0.55, 0.71)|
| ≥13.9                            | 7255           | 1.30  | (1.04, 1.63)| 1.0 (ref)| 0.79 (0.71, 0.87)| 0.79 (0.72, 0.87)|
| APTT (seconds)                   |                |       |            |          |     | 0.2013           |
| <30                              | 7046           | 1.35  | (1.04, 1.74)| 1.0 (ref)| 0.76 (0.68, 0.85)| 0.67 (0.60, 0.76)|
| ≥30                              | 7144           | 1.36  | (1.10, 1.68)| 1.0 (ref)| 0.76 (0.69, 0.84)| 0.83 (0.75, 0.92)|
5. Conclusions

In this large cohort, we found that BMI was independently associated with severity and all-cause mortality of critically ill patients with AKI. Overweight and obesity were associated with increased risk of AKI stage III; however, they were predictive of a relatively lower mortality risk in these patients.

Data Availability

The clinical data used to support the findings of this study were supplied by the Multiparameter Intelligent Monitoring in Intensive Care Database III version 1.4 (MIMIC-III v.1.4). Although the database is publicly and freely available, researchers must complete the National Institutes of Health’s web-based course known as Protecting Human Research Participants to apply for permission to access the database.

Ethical Approval

The MIMIC-III database has received ethical approval from the institutional review boards (IRBs) at Beth Israel Deaconess Medical Center and Massachusetts Institute of Technology. Because the database does not contain protected health information, a waiver of the requirement for informed consent was included in the IRB approval.

Disclosure

The funders of the project were not involved in study design, collection, data analysis, writing of the report, and publication.

Conflicts of Interest

The authors declare that they have no competing interests.

Acknowledgments

This research was supported by the Scientific Research Foundation of Wenzhou (Y20150038), the Zhejiang Provincial Natural Science Foundation of China (Grants nos. LY19H150002 and LY13H150007), and the Clinical Research Foundation of the 2nd Affiliated Hospital of Wenzhou Medical University (SAHoWMU-CR2019-11-423).

Supplementary Materials

Table 1: baseline characteristics of participants according to AKI classification. BMI: body mass index; SBP: systolic blood pressure; DBP: diastolic blood pressure; MBP: mean blood pressure; BUN: blood urea nitrogen; WBC: white blood cell; PT: prothrombin time; APTT: activated partial thromboplastin time; INR: international normalized ratio; SOFA: sequential organ failure assessment; SAPSII: simplified acute physiology score II. HRs (95 CIs) were derived from the Cox proportional hazards regression models.

References

[1] N. S. Kanagasundaram, “Pathophysiology of ischaemic acute kidney injury,” Annals of Clinical Biochemistry, vol. 52, no. 2, pp. 193–205, 2015.
[2] S. Uchino, J. A. Kellum, R. Bellomo et al., “Acute renal failure in critically ill patients: a multinational, multicenter study,” JAMA, vol. 294, no. 7, pp. 813–818, 2005.
[3] J. G. Hofhuis, H. F. van Stel, A. J. Schrijvers, J. H. Rommes, and P. E. Spronk, “The effect of acute kidney injury on long-term
Acute kidney injury is surprisingly common and a powerful predictor of mortality in surgical sepsis, in critically ill patients: a cohort analysis, Critical Care Medicine, vol. 75, no. 3, pp. 432–438, 2013.

Body mass index is associated with hospital mortality in critically ill patients: an observational cohort study, Critical Care Medicine, vol. 32, no. 4, pp. 998–1003, 2004.

Impact of body mass index on incidence and prognosis of acute kidney injury requiring renal replacement therapy, Intensive Care Medicine, vol. 36, no. 7, pp. 1221–1228, 2010.

The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure, Intensive Care Medicine, vol. 22, no. 7, pp. 707–710, 1996.
American multicenter study,” *JAMA*, vol. 270, no. 24, pp. 2957–2963, 1993.

[31] J. P. Vandenbroucke, E. von Elm, D. G. Altman et al., “Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration,” *International journal of surgery (London, England)*, vol. 12, no. 12, pp. 1500–1524, 2014.

[32] A. Anzueto, F. Frutos-Vivar, A. Esteban et al., “Influence of body mass index on outcome of the mechanically ventilated patients,” *Thorax*, vol. 66, no. 1, pp. 66–73, 2011.

[33] C. J. Lavie, R. V. Milani, and H. O. Ventura, “Obesity and cardiovascular disease: risk factor, paradox, and impact of weight loss,” *Journal of the American College of Cardiology*, vol. 53, no. 21, pp. 1925–1932, 2009.

[34] J. E. Hall, J. M. do Carmo, A. A. da Silva, Z. Wang, and M. E. Hall, “Obesity-induced hypertension: interaction of neurohumoral and renal mechanisms,” *Circulation Research*, vol. 116, no. 6, pp. 991–1006, 2015.

[35] R. Anari, R. Amani, S. M. Latifi, M. Veissi, and H. Shahbazian, “Association of obesity with hypertension and dyslipidemia in type 2 diabetes mellitus subjects,” *Diabetes & metabolic syndrome*, vol. 11, no. 1, pp. 37–41, 2017.

[36] P. R. Schauer, D. L. Bhatt, J. P. Kirwan et al., “Bariatric surgery versus intensive medical therapy for diabetes—3-year outcomes,” *The New England Journal of Medicine*, vol. 370, no. 21, pp. 2002–2013, 2014.

[37] T. D. Adams, R. E. Gress, S. C. Smith et al., “Long-term mortality after gastric bypass surgery,” *The New England Journal of Medicine*, vol. 357, no. 8, pp. 753–761, 2007.

[38] S. Li, X. Hu, J. Xu et al., “Increased body mass index linked to greater short- and long-term survival in sepsis patients: a retrospective analysis of a large clinical database,” *International Journal of Infectious Diseases*, vol. 87, pp. 109–116, 2019.

[39] J. E. Hall, E. D. Crook, D. W. Jones, M. R. Wofford, and P. M. Dubbert, “Mechanisms of obesity-associated cardiovascular and renal disease,” *The American Journal of the Medical Sciences*, vol. 324, no. 3, pp. 127–137, 2002.

[40] J. E. Hall, J. M. do Carmo, A. A. da Silva, Z. Wang, and M. E. Hall, “Obesity, kidney dysfunction and hypertension: mechanistic links,” *Nature Reviews Nephrology*, vol. 15, no. 6, pp. 367–385, 2019.

[41] E. S. Kim, H. J. Kim, Y. J. Kim et al., “Resistive index as a predictor of acute kidney injury caused by an angiotensin converting enzyme inhibitor or angiotensin II receptor blocker in chronic kidney disease patients,” *Kidney research and clinical practice*, vol. 32, no. 4, pp. 158–163, 2013.

[42] R. S. Ahima, “Revisiting leptin’s role in obesity and weight loss,” *The Journal of Clinical Investigation*, vol. 118, no. 7, pp. 2380–2383, 2008.

[43] R. H. Mak, W. Cheung, R. D. Cone, and D. L. Marks, “Leptin and inflammation-associated cachexia in chronic kidney disease,” *Kidney International*, vol. 69, no. 5, pp. 794–797, 2006.

[44] M. Ambarkar, S. V. Pemmaraju, S. Gouroju et al., “Adipokines and their relation to endothelial dysfunction in patients with chronic kidney disease,” *Journal of clinical and diagnostic research : JCDDR*, vol. 10, no. 1, 2016.

[45] J. Niedziela, B. Hudzik, N. Niedziela et al., “The obesity paradox in acute coronary syndrome: a meta-analysis,” *European Journal of Epidemiology*, vol. 29, no. 11, pp. 801–812, 2014.